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Background: Breast neoplasms are the second most common type of cancer worldwide, and radiation therapy is a
key component of their treatment. Acute skin reactions are one of the most common side effects of radiation
therapy, and prevention of this adverse event has been investigated in several studies. However, a clinically
applicable, preventative treatment remains unavailable. It has been demonstrated that application of a low-power
laser can promote tissue repair. Therefore, the aim of this trial is to evaluate the effectiveness of an indium gallium
aluminum phosphorus (InGaAIP) laser operated at 660 nm in preventing radiodermatitis in women undergoing
adjuvant radiotherapy for breast cancer.
Methods/Design: This is a two-arm, randomized controlled trial. A total of 52 patients undergoing radiotherapy for
breast cancer (stages I to III) will be enrolled. Patients will be randomly assigned to an intervention group to receive
laser therapy (n = 26) or a control group to receive a placebo (n = 26). The laser or placebo will be applied five days
a week, immediately before each radiotherapy session. Skin reactions will then be graded weekly by a nurse, a
radiotherapist, and an oncologist (all of whom will be blinded) using the Common Toxicity Criteria (CTC) developed
by the National Cancer Institute and the Acute Radiation Morbidity Scoring Criteria developed by the Radiation
Therapy Oncology Group. Patients will also answer a modified visual analogue scale for pain (a self-evaluation
questionnaire). Primary and secondary outcomes will be the prevention of radiodermatitis and pain secondary to
radiodermatitis, respectively.
Discussion: The ideal tool for preventing radiodermatitis is an agent that mediates DNA repair or promotes cell
proliferation. Application of a low-power laser has been shown to promote tissue repair by reducing inflammation
and inducing collagen synthesis. Moreover, this treatment approach has not been associated with adverse events
and is cost-effective. Thus, the results of this ongoing trial may establish whether use of a low-power laser
represents an ideal treatment option for the prevention of radiodermatitis.
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Approximately 90% of patients with breast cancer who
are treated with adjuvant radiotherapy develop acute
skin reactions [1]. Interventions to reduce this adverse
side effect are needed since radiodermatitis may impact
a patient’s adherence to treatment, and, with increased
severity, can lead to the discontinuation of a potentially
curative treatment [1,2].
Acute radiodermatitis is a reaction caused by secon-
dary skin exposure to ionizing radiation. Ionizing radi-
ation impairs the ability of cells to proliferate quickly,
and this leads to a skin reaction. This complex process
involves DNA damage and changes in proteins, lipids,
and carbohydrates. At the tissue level, this injury to the
skin includes basal cell destruction and depletion of skin
cells. As the migration of basal cells to the skin surface
is compromised by radiation, flaking of the skin develops
[1,3]. Initially manifesting as erythema between the first
and fourth weeks of radiation treatment, this condition
can progress to ulceration up to three months after
treatment [4,5].
Known risk factors for radiodermatitis include total
radiation dose, fractionation scheme, type of equipment
used, volume of tissue irradiated (such as breast vol-
ume), and the radiosensitivity of the tissues involved. It
is believed that patient-related factors, such as smoking
habit, chronic diseases (including diabetes mellitus), and
concomitant anticancer treatment can also interfere with
skin reactions by affecting the healing process [6].
Prevention of this adverse event has been investigated
in several studies [3,7-9]. However, there is currently no
clinically applicable prophylaxis available. As suggested
by the Cancer Care Ontario Guidelines, the efficacy of
topical agents remains controversial as well, and there is
not sufficient evidence to indicate a prophylactic regi-
men using these agents for radiodermatitis.
Bolderston et al. [7] conducted a systematic review on
the prevention and management of acute skin reactions
related to radiation therapy. Unfortunately, the trials
included in this systematic review were highly heteroge-
neous (the trials evaluated different kinds of treatments
such as topical steroid creams, washing practices, sucral-
fate, Biafine cream, oral enzymes, amifostine, topical acid
cream, aloe vera, chamomile cream, and dressings), and
they concluded that there was insufficient evidence to
support or refute specific topical or oral agents for the
prevention or management of acute skin reactions [7].
Although various topical agents have been used to
treat acute skin reactions, there is not sufficient evidence
to establish a standardized recommendation for their
application [3,7]. In 2012, Zhang et al. [3] performed a
meta-analysis on the use of topical agent therapy for the
prevention and treatment of radiodermatitis. They con-
cluded that topical agents could not prevent or treatradiodermatitis, probably because the topical agents cho-
sen did not address the pathophysiology of radiodermati-
tis. An ideal agent for the prevention of radiodermatitis
would mediate the repair of DNA damage or promote cell
proliferation [3].
It was demonstrated that the cumulative effect of a
low-power laser, when used at the appropriate dose, pro-
moted tissue repair, possibly due to reduced inflamma-
tion and to the induction of collagen synthesis [10].
Specifically, laser treatment had a positive effect on
injured fibroblasts by directly stimulating their growth,
by affecting the expression of genes related to cell migra-
tion, DNA repair, ion channels, membrane potential,
and cellular metabolism. It is hypothesized that the sum
of these events contribute to ulcer healing through an
increase in collagen synthesis, microcirculation, and
suppression of apoptosis [11].
The application of a low-power laser for the preven-
tion of oral mucositis is already well-established [12-15].
Moreover, the application of laser treatments to patients
with breast cancer has also been found to be safe [16],
and this method currently represents an option for treat-
ment of lymphedema, a side effect of the surgical treatment
of breast cancer [17-20]. Furthermore, a meta-analysis
demonstrated that there are no side effects due to use of a
laser during these treatments [14].
Previously, only one study has investigated the use of
photomodulation by using light emitting diodes (LEDs)
[21]. In this study, breast cancer patients were treated
with radiation therapy following a lumpectomy, and LED
photomodulation treatments were administered imme-
diately following intensity-modulated radiation therapy
(IMRT). These photomodulation treatments were found
to reduce the incidence of skin reactions having a National
Cancer Institute (NCI) grading of 1, 2, or 3 [21].
When laser therapy was applied to oral mucositis sec-
ondary to radiotherapy and chemotherapy, the incidence
of grade 3 mucositis was reduced from 35.22 to 7.62%
[22]. Based on these results, it is hypothesized that laser
treatments may also represent a prophylaxis for radio-
dermatitis, particularly since there is currently no effective
treatment for this side effect of radiotherapy. Therefore,
this randomized controlled trial was designed to assess
the effectiveness of laser therapy for the prevention of
radiodermatitis.Methods/Design
Study aims
The primary aim is to evaluate whether an indium gal-
lium aluminum phosphorus (InGaAIP) laser operated at
660 nm can minimize the occurrence of radiodermatitis
in breast cancer patients undergoing adjuvant radiother-
apy. The secondary aim is to evaluate the ability of these
Costa et al. Trials 2014, 15:330 Page 3 of 6
http://www.trialsjournal.com/content/15/1/330laser treatments to decrease the pain associated with
radiodermatitis.
Ethical issues
Ethical Committees of the Universidade do Vale do
Sapucaí and the Hospital do Cancer de Barretos have
approved this study protocol (approval numbers 564.777
and 626.876 respectively). Only participants who agree
to provide written informed consent will be enrolled.
Study design and setting
This is a two-arm, parallel group, randomized controlled
trial that will be conducted at the Hospital do Cancer de
Barretos (Brazil), which treats annually approximately
600 patients who undergo adjuvant radiotherapy. Patients
will be recruited from the radiotherapy department of this
hospital.
Sample size
This study is powered to detect a reduction in the rate
of radiodermatitis grade 3. To achieve an acceptable type
1 error of 5% and a type 2 error of 20%, the required
sample size is 26 patients per arm (one-tailed test). We
were not able to find data from breast cancer patients to
use in the sample size calculation, thus it was performed
based on data from the study of Bensadoun et al., which
used a low-energy He/Ne laser to prevent radiation-
induced mucositis in head and neck cancer patients [22].
These authors found not only a reduction in mucositis
grade 3 (35.22% occurrence in control group versus
7.62% in laser group), but also a reduction in oral pain
as assessed by patients, due to the preventive use of laser
application.
Inclusion criteria
Female patients older than 18 years of age with a histo-
logical diagnosis of breast cancer (stages I to III) who
underwent breast-conserving surgery or mastectomy with-
out breast reconstruction with proposed adjuvant conven-
tional radiotherapy according to the clinical protocol of
Hospital do Cancer de Barretos (at full volume: ‘hot
spot’ ≤115%, according to the International Commis-
sion on Radiation Units and Measurements (ICRU))
will be enrolled in this trial.
All patients will undergo radiotherapy according to the
radiotherapy protocol of Hospital do Cancer de Barretos.
The maximal point dose will not exceed 115% of the
prescription whole breast dose (for example, the max-
imal point dose will not exceed 57.5 Gy for a prescribed
dose of 50 Gy).
Exclusion criteria
Patients who have undergone a mastectomy with im-
mediate breast reconstruction and those suffering fromcollagen diseases will be excluded from this study.
Patients who do not meet the criteria for planning radio-
therapy will also be excluded (patients with maximal
point dose >115%).Group assignment
All patients undergoing radiotherapy for breast cancer
will be assessed for eligibility criteria (including the dose
of radiation) immediately after the radiotherapy plan-
ning. Eligible patients will be informed about the study
and invited to participate. A total of 52 patients un-
dergoing radiotherapy for breast cancer (stages I to III)
will be prospectively enrolled after providing informed
consent.
The participants will be allocated to an intervention
group (laser therapy, n = 26) or a to a control group
(placebo, n = 26). The latter will receive treatment from
a deactivated laser unit that does not deliver radiation.
Group allocation will be determined using randomly
generated computer sequences (Software R™, R Founda-
tion for Statistical Computing, Vienna, Austria) [22].
The allocation concealment will be achieved by using a
sealed opaque envelope with patient’s number in the
study, which will be opened by the physiotherapist
responsible for the intervention immediately before the
first laser or placebo application.
The radiotherapist, the oncologist, the nurse, and the
patients will be blinded to the allocation outcome. Only
those administering the intervention (physiotherapist)
will know the allocation of patients into the groups.Baseline procedures and interventions
Patients will undergo radiotherapy according to the
radiotherapy protocol of Hospital do Cancer de Barretos.
Protocols vary from 25 to 30 sessions of radiotherapy,
taking into account the need of sequential tumor bed
boost in some patients.
A pilot study was performed to adjust laser application
methods, since there is no data about this in literature.
For both intervention and control groups, a center point
will be marked within an 18 × 18 cm [2] size area. Then,
a plastic guide with a grid of 35 points will be centered
over the surgical bed to guide the application of the laser
or placebo (Figure 1). Five days a week, patients in
intervention group will receive a laser treatment that is
applied for 22 minutes (38 seconds each point) within
12 hours prior to each radiotherapy session. For the con-
trol group, the same procedure will be performed with-
out activation of the laser. However, the appearance and
noise of this placebo will be identical to the treatment
group. In addition, both groups of patients will be blind-
folded and will wear protective goggles during the
treatments.
Figure 1 Plastic guide with a grid of 35 points to guide the
application of the laser or placebo.
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radiotherapy fields. In patients where this is not possible
(patients radiating supraclavicular fossa), the nipple will
be used as reference point for the center; and, in mastec-
tomy patients, the midpoint between the tattoos will be
used (as routine for radiation therapy, the patients un-
dergoing radiation therapy in the hospital are routinely
tattooed in two points, mid-axillary line and sternal; its
midpoint roughly corresponds to nipple’s localization).
Patients allocated to the intervention group will re-
ceive laser treatments using a Photon Laser III (DMC™,
São Carlos - SP, Brazil), approved by ANVISA (Agência
Nacional de Vigilância Sanitária) for medicinal purposes.
This InGaAIP laser emits a pulsed 660 nm beam with
contact, with an average output of 80 mW. The laser
energy is 3 J, with a power density of 80 mW and a dose
emission of 108 J/cm [2]. The distribution of the light
beam in the marking will be on points with a radius of
1 cm. Clinical and demographic data will be collected
before the first radiotherapy session, including schemes
of chemotherapy, breast volume, smoking habit, chronic
diseases, and concomitant anticancer treatment, as they
are factors that can interfere with the development of
radiodermatitis.
After the second week of radiotherapy, patients will be
evaluated for radiodermatitis weekly, after the laser or
placebo application. They will also complete a modified
visual analogue scale for pain (a patient self-evaluation
questionnaire, validated for use in Brazil) [23]. Skin reac-
tions and pain will be continue to be graded weekly untilthe end of treatment, and this evaluation will be inde-
pendently performed by three previously trained evalua-
tors: a nurse, a radiation oncologist, and an oncologist.
The Common Toxicity Criteria (CTC 4.0), developed by
the NCI [24], and the Acute Radiation Morbidity
Scoring Criteria developed by the Radiation Therapy
Oncology Group (RTOG) [5] will be used as guidelines.
The CTC was first described in 1982 and the version
we will is the 4.0. It classifies radiodermatitis in degrees:
1 (faint erythema or dry desquamation), 2 (moderate to
brisk erythema; patch moist desquamation, mostly
confined to skin folds and creases; moderate edema), 3
(moist desquamation in areas other than skin folds and
creases; bleeding induced by minor trauma or abrasion),
4 (life-threatening consequences; skin necrosis or ul-
ceration of full thickness dermis; spontaneous blee-
ding from involved site; skin graft indicated) and 5
(death) [24].
Also in 1982, The RTOG developed the Criterion
score for Acute Radiation Morbidity - Acute Radiation
Morbidity Scoring Criteria, to classify the effects of ra-
diotherapy. This criterion identifies grades 0 (no change
over baseline), 1 (follicular faint or dull erythema, epil-
ation, dry desquamation, decreased sweating), 2 (tender
or bright erythema, patchy moist desquamations, moder-
ate edema), 3 (confluent, moist desquamation other than
skin folds, pitting edema) and 4 (ulceration, hemorrhage,
necrosis) [5].
The visual analogue scale for pain was adapted and
validated for use in Brazil by Ferraz et al. [23], in 1990.
It is a patient self-evaluation scale, ranging from 0 to
10, with 0 meaning no pain and 10 meaning maxi-
mum pain [23].
Grading of radiodermatitis and pain assessment and
will be repeated 90 days after the beginning of radiother-
apy. If any of the evaluators perceive any adverse event
that could be attributed to the intervention, or if the pa-
tient withdraws consent at any time, this patient will be
immediately withdrawn from the study.
Both arms will follow the institutional skin care proto-
col, which consists of chamomile cream 10% with sili-
cone cream 5.5%. This concoction will be used three
times a day for the duration of the radiotherapy.
Outcome measures
The primary outcome is assessment and grading of radio-
dermatitis. The secondary outcome is pain assessment.
Endpoints
Participation is in this study is considered complete
90 days after the beginning of radiotherapy. However,
exit points include a delay in radiotherapy greater than
10 days (if the break is not caused by radiodermatitis), or
non-attendance of the patient at weekly review sessions.
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Statistical analyses will be performed using Statistical
Package for Social Sciences (SPSS) software v.18 (SPSS
Inc., Chicago, Illinois, United States) and Software R™, (R
Foundation for Statistical Computing, Vienna, Austria)
[25]. The rejection level for the null hypothesis will be
fixed at 5% (α ≤0.05). The pondered kappa coefficient will
be used to compare responses among evaluators. The
McNemar test will be used to compare levels of pain
between groups (one test will be performed weekly). For
inter-group assessments of the proportion of radioderma-
titis, the Chi-square test will be used to compare group
intervention and control.
Discussion
Radiodermatitis is one of the most common side effects
of radiation therapy, and despite advances in treatment
techniques, skin reactions remain inevitable [1,26]. More-
over, this adverse event can represent a significant source
of pain or discomfort and can lead to limited daily activ-
ities, a decrease in quality of life, decreased patient adher-
ence to treatment, or even an interruption of treatment
[1]. Consequently, it is important that efforts be made to
prevent radiodermatitis.
Low-power laser treatments have been well-established
for the prevention and treatment of oral mucositis and for
the treatment of lymphedema [12-15,17-20]. Moreover,
according to a recent meta-analysis on radiation-induced
mucositis, low-level laser therapy at a dose of 2 to 3 J/cm
[2] that was administered in daily applications, or at
least three times a week, did not result in any adverse
effects [14].
Regarding lymphedema, a recent systematic review
presented moderate to strong evidence that low-level laser
treatments are effective for the management of this con-
dition [17]. For the 230 patients analyzed, a dose of 1 to
2 J/cm [2] per point applied, with several points covering
the fibrotic area, reduced limb volume [17]. Furthermore,
Carati et al. [20] conducted a prospective, double-blind,
randomized controlled study with 61 patients who under-
went mastectomy and then developed lymphedema. There
were 28 patients in the placebo group and 33 patients in
the treatment group. For the latter, a 904 nm RianCorp
LTU 904H laser was applied to 17 points at 2 cm intervals
(using a plastic guide) in the region of the axilla for each
patient. For the placebo group, the laser unit was deac-
tivated and no radiation was delivered. Moreover, this
unit was indistinguishable from the active unit. The
total energy applied was 1.5 J/cm [2], and this treatment
was found to reduce the volume of arm lymphedema in
31% of the patients that completed three months of this
treatment [20].
Despite all the training conducted for the grading of
radiodermatitis, the CTC and RTOG’s scales are dependenton observers, and this may lead to a grading bias. Unfor-
tunately we cannot completely eliminate subjectivity in
evaluating the radiodermatitis grade.
In the absence of clinical guidelines for the prevention
of radiodermatitis, treatment of this side effect of radi-
ation remains a challenge. However, based on the effect-
iveness of laser treatments for the prevention of oral
mucositis, a clinical trial to investigate the beneficial ap-
plication of laser treatments as a prophylaxis for radio-
dermatitis was established. It is possible that the results
of this trial may provide a standard treatment for the
prevention of acute skin reactions that develop following
radiotherapy.
Trial status
Recruitment began on April 2014, and it is ongoing. A
total of 26 patients were enrolled by the end of June
2014.
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